688687.SS Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 23:30):

Beijing Kawin Technology Share-Holding Co., Ltd. engages in the development and production of pharmaceutical products primarily in the areas of liver diseases in China...

Stats
Today's Volume	3.03M
Average Volume	6.41M
Market Cap	4.85B
EPS	CNY0.310 ( 2023-10-26 )
Last Dividend	CNY0 ( N/A )
Next Dividend	CNY0 ( N/A )
P/E	40.83
ATR14	CNY0.111 (0.38%)

Volume Correlation

Long: -0.16 (neutral)

Short: -0.98 (very strong negative)

Signal:(50.808) Neutral

Beijing Kawin Technology Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Beijing Kawin Technology Correlation - Currency/Commodity

0.59
( weak )

0.57
( weak )

0.00
( neutral )

0.64
( weak )

0.46
( neutral )

-0.67
( moderate negative )

Beijing Kawin Technology Financials

Annual	2023
Revenue:	CNY1.41B
Gross Profit:	CNY1.18B (83.55 %)
EPS:	CNY0.700

Q1	2024
Revenue:	CNY212.67M
Gross Profit:	CNY167.41M (78.72 %)
EPS:	CNY0.130

Q4	2023
Revenue:	CNY409.68M
Gross Profit:	CNY344.45M (84.08 %)
EPS:	CNY0.160

Q3	2023
Revenue:	CNY433.59M
Gross Profit:	CNY367.50M (84.76 %)
EPS:	CNY0.310

Financial Reports:

No articles found.

Beijing Kawin Technology

Beijing Kawin Technology Share-Holding Co., Ltd. engages in the development and production of pharmaceutical products primarily in the areas of liver diseases in China. The company's products include recombinant human interferon alfa-2b injection and compound glycyrrhizin. It provides active pharmaceutical ingredients; clinical research services for biological product development, which include drug substancesfermentation and purification, drug productformulation, and analytical methods development; and contract manufacturing services. The company also serves customers in Pakistan, Colombia, Philippines, Vietnam, Russia, Cambodia, and others. It has strategic partnership with Legend Capital, Haitong Capital, and Cybernaut. The company was founded in 2008 and is based in Beijing, China.